|
private:xceltherainc
|
3719486
|
Jun 4th, 2019 12:00AM
|
Xcelthera Inc
|
86
|
2.00
|
Open
|
Pharmaceuticals
|
Jun 4th, 2019 03:01PM
|
Jun 4th, 2019 03:01PM
|
Xcelthera INC is a new biopharmaceutical company moving towards clinical development stage of novel and most advanced stem cell therapy for a wide range of neurological and cardiovascular diseases with leading technology and ground-breaking medical innovation in cell-based regenerative medicine. Xcelthera is a major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses. We own or have exclusive rights in a portfolio of intellectual property or license rights related to our novel PluriXcel human stem cell technology platforms and Xcel prototypes of human stem cell therapy products, which provide significant competitive advantages for the growth of our business and for the dominance over our target markets. The inception of Xcelthera is driven by the urgent need for clinical translation of human ES cell research discoveries and innovations to address unmet medical challenges in major health problems. Our breakthrough developments in human ES cell research dramatically increase the overall turnover of investments in biomedical sciences to optimal treatment options for a wide range of human diseases. The overall strategy of the Company is to use cutting-edge human stem cell technology to develop clinical-grade functional human neural and cardiac cell therapy products from pluripotent human ES cells as cellular medicine or cellular drugs to provide the next generation of cell-based therapeutic solutions for unmet medical needs. Company is currently offering Series A Convertible Preferred Stock to accredited investors through equity crowdfunding.
|
Open
|
stem cell research, stem cell therapy, regenerative medicine, human embryonic stem cell research, drug development, neurological disorder, cardiovascular disease
|
|
Xcelthera Inc
|
San Diego
|
California
|
US
|
|
|
Xcelthera Inc
|
|
Pharmaceuticals & Biotechnology
|
|
private:xceltherainc
|
3719486
|
Mar 23rd, 2018 12:00AM
|
Xcelthera Inc
|
71
|
2.00
|
Open
|
Pharmaceuticals
|
Mar 23rd, 2017 10:51AM
|
Mar 23rd, 2017 10:51AM
|
Xcelthera INC is a new biopharmaceutical company moving towards clinical development stage of novel and most advanced stem cell therapy for a wide range of neurological and cardiovascular diseases with leading technology and ground-breaking medical innovation in cell-based regenerative medicine. Xcelthera is a major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses. We own or have exclusive rights in a portfolio of intellectual property or license rights related to our novel PluriXcel human stem cell technology platforms and Xcel prototypes of human stem cell therapy products, which provide significant competitive advantages for the growth of our business and for the dominance over our target markets. The inception of Xcelthera is driven by the urgent need for clinical translation of human ES cell research discoveries and innovations to address unmet medical challenges in major health problems. Our breakthrough developments in human ES cell research dramatically increase the overall turnover of investments in biomedical sciences to optimal treatment options for a wide range of human diseases. The overall strategy of the Company is to use cutting-edge human stem cell technology to develop clinical-grade functional human neural and cardiac cell therapy products from pluripotent human ES cells as cellular medicine or cellular drugs to provide the next generation of cell-based therapeutic solutions for unmet medical needs. Company is currently offering Series A Convertible Preferred Stock to accredited investors through equity crowdfunding.
|
|
|
|
|
|
|
|
|
|
Xcelthera Inc
|
|
Pharmaceuticals & Biotechnology
|
|
private:xceltherainc
|
3719486
|
Feb 17th, 2018 12:00AM
|
Xcelthera Inc
|
71
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
Xcelthera INC is a new biopharmaceutical company moving towards clinical development stage of novel and most advanced stem cell therapy for a wide range of neurological and cardiovascular diseases with leading technology and ground-breaking medical innovation in cell-based regenerative medicine. Xcelthera is a major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses. We own or have exclusive rights in a portfolio of intellectual property or license rights related to our novel PluriXcel human stem cell technology platforms and Xcel prototypes of human stem cell therapy products, which provide significant competitive advantages for the growth of our business and for the dominance over our target markets. The inception of Xcelthera is driven by the urgent need for clinical translation of human ES cell research discoveries and innovations to address unmet medical challenges in major health problems. Our breakthrough developments in human ES cell research dramatically increase the overall turnover of investments in biomedical sciences to optimal treatment options for a wide range of human diseases. The overall strategy of the Company is to use cutting-edge human stem cell technology to develop clinical-grade functional human neural and cardiac cell therapy products from pluripotent human ES cells as cellular medicine or cellular drugs to provide the next generation of cell-based therapeutic solutions for unmet medical needs. Company is currently offering Series A Convertible Preferred Stock to accredited investors through equity crowdfunding.
|
|
|
|
|
|
|
|
|
|
Xcelthera Inc
|
|
Pharmaceuticals & Biotechnology
|
|
private:xceltherainc
|
3719486
|
Feb 16th, 2018 12:00AM
|
Xcelthera Inc
|
71
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
Xcelthera INC is a new biopharmaceutical company moving towards clinical development stage of novel and most advanced stem cell therapy for a wide range of neurological and cardiovascular diseases with leading technology and ground-breaking medical innovation in cell-based regenerative medicine. Xcelthera is a major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses. We own or have exclusive rights in a portfolio of intellectual property or license rights related to our novel PluriXcel human stem cell technology platforms and Xcel prototypes of human stem cell therapy products, which provide significant competitive advantages for the growth of our business and for the dominance over our target markets. The inception of Xcelthera is driven by the urgent need for clinical translation of human ES cell research discoveries and innovations to address unmet medical challenges in major health problems. Our breakthrough developments in human ES cell research dramatically increase the overall turnover of investments in biomedical sciences to optimal treatment options for a wide range of human diseases. The overall strategy of the Company is to use cutting-edge human stem cell technology to develop clinical-grade functional human neural and cardiac cell therapy products from pluripotent human ES cells as cellular medicine or cellular drugs to provide the next generation of cell-based therapeutic solutions for unmet medical needs. Company is currently offering Series A Convertible Preferred Stock to accredited investors through equity crowdfunding.
|
|
|
|
|
|
|
|
|
|
Xcelthera Inc
|
|
Pharmaceuticals & Biotechnology
|
|
private:xceltherainc
|
3719486
|
Feb 15th, 2018 12:00AM
|
Xcelthera Inc
|
71
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
Xcelthera INC is a new biopharmaceutical company moving towards clinical development stage of novel and most advanced stem cell therapy for a wide range of neurological and cardiovascular diseases with leading technology and ground-breaking medical innovation in cell-based regenerative medicine. Xcelthera is a major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses. We own or have exclusive rights in a portfolio of intellectual property or license rights related to our novel PluriXcel human stem cell technology platforms and Xcel prototypes of human stem cell therapy products, which provide significant competitive advantages for the growth of our business and for the dominance over our target markets. The inception of Xcelthera is driven by the urgent need for clinical translation of human ES cell research discoveries and innovations to address unmet medical challenges in major health problems. Our breakthrough developments in human ES cell research dramatically increase the overall turnover of investments in biomedical sciences to optimal treatment options for a wide range of human diseases. The overall strategy of the Company is to use cutting-edge human stem cell technology to develop clinical-grade functional human neural and cardiac cell therapy products from pluripotent human ES cells as cellular medicine or cellular drugs to provide the next generation of cell-based therapeutic solutions for unmet medical needs. Company is currently offering Series A Convertible Preferred Stock to accredited investors through equity crowdfunding.
|
|
|
|
|
|
|
|
|
|
Xcelthera Inc
|
|
Pharmaceuticals & Biotechnology
|
|
private:xceltherainc
|
3719486
|
Feb 14th, 2018 12:00AM
|
Xcelthera Inc
|
71
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
Xcelthera INC is a new biopharmaceutical company moving towards clinical development stage of novel and most advanced stem cell therapy for a wide range of neurological and cardiovascular diseases with leading technology and ground-breaking medical innovation in cell-based regenerative medicine. Xcelthera is a major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses. We own or have exclusive rights in a portfolio of intellectual property or license rights related to our novel PluriXcel human stem cell technology platforms and Xcel prototypes of human stem cell therapy products, which provide significant competitive advantages for the growth of our business and for the dominance over our target markets. The inception of Xcelthera is driven by the urgent need for clinical translation of human ES cell research discoveries and innovations to address unmet medical challenges in major health problems. Our breakthrough developments in human ES cell research dramatically increase the overall turnover of investments in biomedical sciences to optimal treatment options for a wide range of human diseases. The overall strategy of the Company is to use cutting-edge human stem cell technology to develop clinical-grade functional human neural and cardiac cell therapy products from pluripotent human ES cells as cellular medicine or cellular drugs to provide the next generation of cell-based therapeutic solutions for unmet medical needs. Company is currently offering Series A Convertible Preferred Stock to accredited investors through equity crowdfunding.
|
|
|
|
|
|
|
|
|
|
Xcelthera Inc
|
|
Pharmaceuticals & Biotechnology
|
|
private:xceltherainc
|
3719486
|
Feb 13th, 2018 12:00AM
|
Xcelthera Inc
|
71
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
Xcelthera INC is a new biopharmaceutical company moving towards clinical development stage of novel and most advanced stem cell therapy for a wide range of neurological and cardiovascular diseases with leading technology and ground-breaking medical innovation in cell-based regenerative medicine. Xcelthera is a major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses. We own or have exclusive rights in a portfolio of intellectual property or license rights related to our novel PluriXcel human stem cell technology platforms and Xcel prototypes of human stem cell therapy products, which provide significant competitive advantages for the growth of our business and for the dominance over our target markets. The inception of Xcelthera is driven by the urgent need for clinical translation of human ES cell research discoveries and innovations to address unmet medical challenges in major health problems. Our breakthrough developments in human ES cell research dramatically increase the overall turnover of investments in biomedical sciences to optimal treatment options for a wide range of human diseases. The overall strategy of the Company is to use cutting-edge human stem cell technology to develop clinical-grade functional human neural and cardiac cell therapy products from pluripotent human ES cells as cellular medicine or cellular drugs to provide the next generation of cell-based therapeutic solutions for unmet medical needs. Company is currently offering Series A Convertible Preferred Stock to accredited investors through equity crowdfunding.
|
|
|
|
|
|
|
|
|
|
Xcelthera Inc
|
|
Pharmaceuticals & Biotechnology
|
|
private:xceltherainc
|
3719486
|
Feb 12th, 2018 12:00AM
|
Xcelthera Inc
|
71
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
Xcelthera INC is a new biopharmaceutical company moving towards clinical development stage of novel and most advanced stem cell therapy for a wide range of neurological and cardiovascular diseases with leading technology and ground-breaking medical innovation in cell-based regenerative medicine. Xcelthera is a major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses. We own or have exclusive rights in a portfolio of intellectual property or license rights related to our novel PluriXcel human stem cell technology platforms and Xcel prototypes of human stem cell therapy products, which provide significant competitive advantages for the growth of our business and for the dominance over our target markets. The inception of Xcelthera is driven by the urgent need for clinical translation of human ES cell research discoveries and innovations to address unmet medical challenges in major health problems. Our breakthrough developments in human ES cell research dramatically increase the overall turnover of investments in biomedical sciences to optimal treatment options for a wide range of human diseases. The overall strategy of the Company is to use cutting-edge human stem cell technology to develop clinical-grade functional human neural and cardiac cell therapy products from pluripotent human ES cells as cellular medicine or cellular drugs to provide the next generation of cell-based therapeutic solutions for unmet medical needs. Company is currently offering Series A Convertible Preferred Stock to accredited investors through equity crowdfunding.
|
|
|
|
|
|
|
|
|
|
Xcelthera Inc
|
|
Pharmaceuticals & Biotechnology
|
|
private:xceltherainc
|
3719486
|
Feb 11th, 2018 12:00AM
|
Xcelthera Inc
|
71
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
Xcelthera INC is a new biopharmaceutical company moving towards clinical development stage of novel and most advanced stem cell therapy for a wide range of neurological and cardiovascular diseases with leading technology and ground-breaking medical innovation in cell-based regenerative medicine. Xcelthera is a major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses. We own or have exclusive rights in a portfolio of intellectual property or license rights related to our novel PluriXcel human stem cell technology platforms and Xcel prototypes of human stem cell therapy products, which provide significant competitive advantages for the growth of our business and for the dominance over our target markets. The inception of Xcelthera is driven by the urgent need for clinical translation of human ES cell research discoveries and innovations to address unmet medical challenges in major health problems. Our breakthrough developments in human ES cell research dramatically increase the overall turnover of investments in biomedical sciences to optimal treatment options for a wide range of human diseases. The overall strategy of the Company is to use cutting-edge human stem cell technology to develop clinical-grade functional human neural and cardiac cell therapy products from pluripotent human ES cells as cellular medicine or cellular drugs to provide the next generation of cell-based therapeutic solutions for unmet medical needs. Company is currently offering Series A Convertible Preferred Stock to accredited investors through equity crowdfunding.
|
|
|
|
|
|
|
|
|
|
Xcelthera Inc
|
|
Pharmaceuticals & Biotechnology
|
|
private:xceltherainc
|
3719486
|
Feb 10th, 2018 12:00AM
|
Xcelthera Inc
|
71
|
2.00
|
Open
|
Pharmaceuticals
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
Xcelthera INC is a new biopharmaceutical company moving towards clinical development stage of novel and most advanced stem cell therapy for a wide range of neurological and cardiovascular diseases with leading technology and ground-breaking medical innovation in cell-based regenerative medicine. Xcelthera is a major innovator in the stem cell research market and one of the first companies formed for clinical applications of human embryonic stem cell (human ES cell) therapeutic utility for unmet medical needs. The Company is the first to hold the proprietary breakthrough technology for large-scale production of high quality clinical-grade pluripotent human ES cell lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses. We own or have exclusive rights in a portfolio of intellectual property or license rights related to our novel PluriXcel human stem cell technology platforms and Xcel prototypes of human stem cell therapy products, which provide significant competitive advantages for the growth of our business and for the dominance over our target markets. The inception of Xcelthera is driven by the urgent need for clinical translation of human ES cell research discoveries and innovations to address unmet medical challenges in major health problems. Our breakthrough developments in human ES cell research dramatically increase the overall turnover of investments in biomedical sciences to optimal treatment options for a wide range of human diseases. The overall strategy of the Company is to use cutting-edge human stem cell technology to develop clinical-grade functional human neural and cardiac cell therapy products from pluripotent human ES cells as cellular medicine or cellular drugs to provide the next generation of cell-based therapeutic solutions for unmet medical needs. Company is currently offering Series A Convertible Preferred Stock to accredited investors through equity crowdfunding.
|
|
|
|
|
|
|
|
|
|
Xcelthera Inc
|
|
Pharmaceuticals & Biotechnology
|